Description: MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The company's existing customer base ranges from large biopharmaceutical companies — including 20 of the top 25 pharmaceutical companies based on 2020 global revenue — to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 13 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.
Home Page: maxcyte.com
MXCT Technical Analysis
9713 Key West Avenue
Rockville,
MD
20850
United States
Phone:
301 944 1700
Officers
| Name | Title |
|---|---|
| Mr. Douglas Arthur Doerfler | Founder, Pres, CEO & Exec. Director |
| Mr. Ronald Evan Holtz CPA, Ph.D. | Chief Financial Officer |
| Dr. J. Stark Thompson Ph.D. | Consultant |
| Dr. Cenk Sumen | Chief Scientific Officer |
| Mr. Sean Menarguez | Director of Investor Relations |
| Mr. Maher Masoud | Exec. VP, Gen. Counsel & Sec. |
| Mr. Thomas Michael Ross | Exec. VP of Global Sales |
| Dr. James Brady Ph.D. | Sr. VP of Technical Applications & Customer Support |
| Dr. Sarah Haecker Meeks Ph.D. | Sr. VP of Bus. Devel. |
| Mr. James Lovgren | Sr. VP of Global Marketing |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1618 |
| Price-to-Sales TTM: | 13.1478 |
| IPO Date: | 2021-07-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 84 |